Tumor immunotherapy: Lessons from autoimmunity

Frontiers in Immunology

Volumn 5, Issue MAY, 2014, Pages

  Maueröder, Christian ^a   Munoz, Luis Enrique ^a   Chaurio, Ricardo Alfredo ^a   Herrmann, Martin ^a   Schett, Georg ^a   Berens, Christian ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Autoimmunity; Cell death; Danger model; Immunotherapy; Tumor microenvironment; Tumor vaccination

Indexed keywords

BCG VACCINE; INTERLEUKIN 10; INTERLEUKIN 8; LIPOCORTIN 5;

APOPTOSIS; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CELL DEATH; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; NOTE; PHAGOCYTOSIS; PROTEIN PHOSPHORYLATION; SCLERODERMA; SYSTEMIC LUPUS ERYTHEMATOSUS; TUMOR IMMUNITY; TUMOR RECURRENCE;

EID: 84987810675     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00212     Document Type: Note

References (64)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144:646-74. doi:10.1016/j.cell.2011.02.013
2. Vesely MD, Schreiber RD. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Ann N Y Acad Sci (2013) 1284:1-5. doi:10.1111/nyas.12105
3. Engel AM, Svane IM, Rygaard J, Werdelin O. MCA sarcomas induced in scid mice are more immunogenic than MCA sarcomas induced in congenic, immunocompetent mice. Scand J Immunol (1997) 45:463-70. doi:10.1046/j.1365-3083.1997.d01-419.x
4. Street SE, Cretney E, Smyth MJ. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood (2001) 97:192-7. doi:10.1182/blood.V97.1.192
5. Ciampricotti M, Vrijland K, Hau CS, Pemovska T, Doornebal CW, Speksnijder EN, et al. Development of metastatic HER2(+) breast cancer is independent of the adaptive immune system. J Pathol (2011) 224:56-66. doi:10.1002/path.2837
6. Stutman O. Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science (1974) 183:534-6. doi:10.1126/science.183.4124.534
7. Manjili MH. Revisiting cancer immunoediting by understanding cancer immune complexity. J Pathol (2011) 224:5-9. doi:10.1002/path.2865
8. Riedl S, Rinner B, Asslaber M, Schaider H, Walzer S, Novak A, et al. In search of a novel target-phosphatidylserine exposed by non-apoptotic tumor cells and metastases of malignancies with poor treatment efficacy. Biochim Biophys Acta (2011) 1808:2638-45. doi:10.1016/j.bbamem.2011.07.026
9. Binder DC, Engels B, Arina A, Yu P, Slauch JM, Fu YX, et al. Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer. Cancer Immunol Res (2013) 1:123-33. doi:10.1158/2326-6066.CIR-13-0058
10. Nauts HC, Fowler GA, Bogatko FH. A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumors in man; a critical analysis of 30 inoperable cases treated by Coley's mixed toxins, in which diagnosis was confirmed by microscopic examination selected for special study. Acta Med Scand Suppl (1953) 276:1-103.
11. Coley WB. Further observations upon the treatment of malignant tumors with the toxins of erysipelas and Bacillus prodigious with a report of 160 cases. Bull Johns Hopkins Hosp (1896) 7:715.
12. Tsung K, Norton JA. Lessons from Coley's toxin. Surg Oncol (2006) 15:25-8. doi:10.1016/j.suronc.2006.05.002
13. Hong EH, Chang SY, Lee BR, Pyun AR, Kim JW, Kweon MN, et al. Intratumoral injection of attenuated Salmonella vaccine can induce tumor microenvironmental shift from immune suppressive to immunogenic. Vaccine (2013) 31:1377-84. doi:10.1016/j.vaccine.2013.01.006
14. Herr HW, Morales A. History of Bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol (2008) 179:53-6. doi:10.1016/j.juro.2007.08.122
15. Matzinger P. The danger model: a renewed sense of self. Science (2002) 296:301-5. doi:10.1126/science.1071059
16. Griffith TS, Ferguson TA. Cell death in the maintenance and abrogation of tolerance: the five Ws of dying cells. Immunity (2011) 35:456-66. doi:10.1016/j.immuni.2011.08.011
17. Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol (2009) 9:353-63. doi:10.1038/nri2545
18. Munoz LE, Lauber K, Schiller M, Manfredi AA, Herrmann M. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol (2010) 6:280-9. doi:10.1038/nrrheum.2010.46
19. Baumann I, Kolowos W, Voll RE, Manger B, Gaipl U, Neuhuber WL, et al. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum (2002) 46:191-201. doi:10.1002/1529-0131(200201)46:1<191::AID-ART10027>3.0.CO;2-K
20. Munoz LE, Janko C, Grossmayer GE, Frey B, Voll RE, Kern P, et al. Remnants of secondarily necrotic cells fuel inflammation in systemic lupus erythematosus. Arthritis Rheum (2009) 60:1733-42. doi:10.1002/art.24535
21. Mottolese M, Buglioni S, Bracalenti C, Cardarelli MA, Ciabocco L, Giannarelli D, et al. Prognostic relevance of altered Fas (CD95)-system in human breast cancer. Int J Cancer (2000) 89:127-32. doi:10.1002/(SICI)1097-0215(20000320)89:2<127::AID-IJC5>3.0.CO;2-4
22. Ivanov VN, Bhoumik A, Krasilnikov M, Raz R, Owen-Schaub LB, Levy D, et al. Cooperation between STAT3 and c-Jun suppresses Fas transcription. Mol Cell (2001) 7:517-28. doi:10.1016/S1097-2765(01)00199-X
23. Chen L, Park SM, Tumanov AV, Hau A, Sawada K, Feig C, et al. CD95 promotes tumour growth. Nature (2010) 465:492-6. doi:10.1038/nature09075
24. Matthess Y, Raab M, Sanhaji M, Lavrik IN, Strebhardt K. Cdk1/cyclin B1 controls Fas-mediated apoptosis by regulating caspase-8 activity. Mol Cell Biol (2010) 30:5726-40. doi:10.1128/MCB.00731-10
25. Cleary ML, Sklar J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA (1985) 82:7439-43. doi:10.1073/pnas.82.21.7439
26. Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science (1997) 275:967-9. doi:10.1126/science.275.5302.967
27. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature (2010) 463:899-905. doi:10.1038/nature08822
28. Fernald K, Kurokawa M. Evading apoptosis in cancer. Trends Cell Biol (2013) 23:620-33. doi:10.1016/j.tcb.2013.07.006
29. Soini Y, Raunio H, Paakko P. High-grade malignant non-Hodgkin's lymphomas differ from low-grade lymphomas in the extent of apoptosis and their expression of bcl-2, mcl-1, bax and p53. Tumour Biol (1998) 19:176-85. doi:10.1159/000030005
30. Stammler G, Sauerbrey A, Zintl F, Volm M. Apoptotic index, Fas and bcl-2 in initial and relapsed childhood acute lymphoblastic leukaemia. Apoptosis (1997) 2:377-83. doi:10.1023/A:1026405707823
31. Bendardaf R, Ristamaki R, Kujari H, Laine J, Lamlum H, Collan Y, et al. Apoptotic index and bcl-2 expression as prognostic factors in colorectal carcinoma. Oncology (2003) 64:435-42. doi:10.1159/000070304
32. Delbridge AR, Valente LJ, Strasser A. The role of the apoptotic machinery in tumor suppression. Cold Spring Harb Perspect Biol (2012) 4:a008789. doi:10.1101/cshperspect.a008789
33. Uderhardt S, Herrmann M, Oskolkova OV, Aschermann S, Bicker W, Ipseiz N, et al. 12/15-Lipoxygenase orchestrates the clearance of apoptotic cells and maintains immunologic tolerance. Immunity (2012) 36:834-46. doi:10.1016/j.immuni.2012.03.010
34. Steinman RM, Turley S, Mellman I, Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med (2000) 191:411-6. doi:10.1084/jem.191.3.411
35. Jordan P, Carmo-Fonseca M. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci (2000) 57:1229-35. doi:10.1007/PL00000762
36. Del Gaizo Moore V, Letai A. BH3 profiling-measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett (2013) 332:202-5. doi:10.1016/j.canlet.2011.12.021
37. Sarosiek KA, Ni Chonghaile T, Letai A. Mitochondria: gatekeepers of response to chemotherapy. Trends Cell Biol (2013) 23:612-9. doi:10.1016/j.tcb.2013.08.003
38. Chaurio R, Janko C, Schorn C, Maueröder C, Bilyy R, Gaipl U, et al. UVB-irradiated apoptotic cells induce accelerated growth of co-implanted viable tumor cells in immune competent mice. Autoimmunity (2013) 46:317-22. doi:10.3109/08916934.2012.754433
39. Lauber K, Munoz LE, Berens C, Jendrossek V, Belka C, Herrmann M. Apoptosis induction and tumor cell repopulation: the Yin and Yang of radiotherapy. Radiat Oncol (2011) 6:176. doi:10.1186/1748-717X-6-176
40. Gregory CD, Pound JD. Cell death in the neighbourhood: direct microenvironmental effects of apoptosis in normal and neoplastic tissues. J Pathol (2011) 223:177-94. doi:10.1002/path.2792
41. Hochreiter-Hufford A, Ravichandran KS. Clearing the dead: apoptotic cell sensing, recognition, engulfment, and digestion. Cold Spring Harb Perspect Biol (2013) 5:a008748. doi:10.1101/cshperspect.a008748
42. Lauber K, Bohn E, Kröber SM, Xiao Y-J, Blumenthal SG, Lindemann RK, et al. Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell (2003) 113:717-30. doi:10.1016/S0092-8674(03)00422-7
43. Weigert A, Cremer S, Schmidt MV, von Knethen A, Angioni C, Geisslinger G, et al. Cleavage of sphingosine kinase 2 by caspase-1 provokes its release from apoptotic cells. Blood (2010) 115:3531-40. doi:10.1182/blood-2009-10-243444
44. Gude DR, Alvarez SE, Paugh SW, Mitra P, Yu J, Griffiths R, et al. Apoptosis induces expression of sphingosine kinase 1 to release sphingosine-1-phosphate as a "come-and-get-me" signal. FASEB J (2008) 22:2629-38. doi:10.1096/fj.08-107169
45. Weigert A, Tzieply N, von Knethen A, Johann AM, Schmidt H, Geisslinger G, et al. Tumor cell apoptosis polarizes macrophages role of sphingosine-1-phosphate. Mol Biol Cell (2007) 18:3810-9. doi:10.1091/mbc.E06-12-1096
46. Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, et al. Macrophage polarization in tumour progression. Semin Cancer Biol (2008) 18:349-55. doi:10.1016/j.semcancer.2008.03.004
47. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature (1997) 390:350-1. doi:10.1038/37022
48. Reiter I, Krammer B, Schwamberger G. Cutting edge: differential effect of apoptotic versus necrotic tumor cells on macrophage antitumor activities. J Immunol (1999) 163:1730-2.
49. Takanami I, Takeuchi K, Kodaira S. Tumor-associated macrophage infiltration in pulmonary adenocarcinoma: association with angiogenesis and poor prognosis. Oncology (1999) 57:138-42. doi:10.1159/000012021
50. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med (2010) 362:875-85. doi:10.1056/NEJMoa0905680
51. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med (1986) 315:1650-9. doi:10.1056/NEJM198612253152606
52. Bondanza A, Zimmermann VS, Rovere-Querini P, Turnay J, Dumitriu IE, Stach CM, et al. Inhibition of phosphatidylserine recognition heightens the immunogenicity of irradiated lymphoma cells in vivo. J Exp Med (2004) 200:1157-65. doi:10.1084/jem.20040327
53. Frey B, Schildkopf P, Rödel F, Weiss EM, Munoz LE, Herrmann M, et al. AnnexinA5 renders dead tumor cells immunogenic-implications for multimodal cancer therapies. J Immunotoxicol (2009) 6:209-16. doi:10.3109/15476910903204058
54. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer (2012) 12:860-75. doi:10.1038/nrc3380
55. Munoz LE, Franz S, Pausch F, Fürnrohr B, Sheriff A, Vogt B, et al. The influence on the immunomodulatory effects of dying and dead cells of Annexin V. J Leukoc Biol (2007) 81:6-14. doi:10.1189/jlb.0306166
56. Garg AD, Krysko DV, Vandenabeele P, Agostinis P. The emergence of phox-ER stress induced immunogenic apoptosis. Oncoimmunology (2012) 1:786-8. doi:10.4161/onci.19750
57. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol (2005) 1:112-9. doi:10.1038/nchembio0905-234a
58. Brennan MA, Cookson BT. Salmonella induces macrophage death by caspase-1-dependent necrosis. Mol Microbiol (2000) 38:31-40. doi:10.1046/j.1365-2958.2000.02103.x
59. -1 infection. Nature (2014) 505:509-14. doi:10.1038/nature12940
60. Vacchelli E, Senovilla L, Eggermont A, Fridman WH, Galon J, Zitvogel L, et al. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology (2013) 2:e23510. doi:10.4161/onci.23510
61. Maueröder C, Chaurio RA, Platzer S, Munoz LE, Berens C. Model systems for rapid and slow induction of apoptosis obtained by inducible expression of pro-apoptotic proteins. Autoimmunity (2013) 46:329-35. doi:10.3109/08916934.2012.752463
62. Lohmann C, Muschaweckh A, Kirschnek S, Jennen L, Wagner H, Häcker G. Induction of tumor cell apoptosis or necrosis by conditional expression of cell death proteins: analysis of cell death pathways and in vitro immune stimulatory potential. J Immunol (2009) 182:4538-46. doi:10.4049/jimmunol.0803989
63. Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, et al. Bcl-2 antiapoptotic proteins inhibit beclin 1-dependent autophagy. Cell (2005) 122:927-39. doi:10.1016/j.cell.2005.07.002
64. Joseph CG, Darrah E, Shah AA, Skora AD, Casciola-Rosen LA, Wigley FM, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science (2014) 343:152-7. doi:10.1126/science.1246886